NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis $9.34 -0.11 (-1.16%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Phathom Pharmaceuticals Stock (NASDAQ:PHAT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PHAT alerts:Sign Up Key Stats Today's Range$8.95▼$9.9850-Day Range$8.73▼$19.2352-Week Range$6.07▼$19.71Volume1.22 million shsAverage Volume1.92 million shsMarket Capitalization$638.67 millionP/E RatioN/ADividend YieldN/APrice Target$22.50Consensus RatingModerate Buy Company OverviewPhathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Read More… 50-year Wall Street legend: “Sell this tech stock NOW” (Ad)Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. Phathom Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks53rd Percentile Overall ScorePHAT MarketRank™: Phathom Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 561st out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePhathom Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Phathom Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.74) to ($3.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Phathom Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.52% of the outstanding shares of Phathom Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently decreased by 0.63%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted25.52% of the outstanding shares of Phathom Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently decreased by 0.63%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.91 News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest6 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders24.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Stock News HeadlinesCraig-Hallum Sticks to Their Buy Rating for Phathom Pharmaceuticals (PHAT)November 13, 2024 | markets.businessinsider.comPhathom Pharmaceuticals (PHAT) Receives a Buy from Stifel NicolausNovember 11, 2024 | markets.businessinsider.comBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. November 23, 2024 | WealthPress (Ad)Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call TranscriptNovember 10, 2024 | seekingalpha.comPhathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...November 8, 2024 | finance.yahoo.comPhathom Pharmaceuticals Reports Significant Revenue GrowthNovember 8, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Surpasses Expectations: Strong Q3 Performance and Bullish Outlook Drive Increased Revenue Estimates and Price TargetNovember 8, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look ForNovember 6, 2024 | finance.yahoo.comSee More Headlines PHAT Stock Analysis - Frequently Asked Questions How have PHAT shares performed this year? Phathom Pharmaceuticals' stock was trading at $9.13 at the beginning of 2024. Since then, PHAT shares have increased by 2.3% and is now trading at $9.34. View the best growth stocks for 2024 here. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.12. The firm had revenue of $0.68 million for the quarter, compared to analysts' expectations of $0.93 million. When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Top institutional investors of Phathom Pharmaceuticals include Jennison Associates LLC (9.84%), Portolan Capital Management LLC (2.49%), Checkpoint Capital L.P. (2.20%) and FMR LLC (1.91%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi and Asit Parikh. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings3/07/2024Today11/23/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHAT CUSIPN/A CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$22.50 High Stock Price Target$28.00 Low Stock Price Target$12.00 Potential Upside/Downside+140.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($5.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-201,590,000.00 Net Margins-1,292.14% Pretax Margin-1,292.14% Return on EquityN/A Return on Assets-79.57% Debt Debt-to-Equity RatioN/A Current Ratio5.73 Quick Ratio5.68 Sales & Book Value Annual Sales$680,000.00 Price / Sales939.22 Cash FlowN/A Price / Cash FlowN/A Book Value($2.74) per share Price / Book-3.41Miscellaneous Outstanding Shares68,380,000Free Float51,898,000Market Cap$638.67 million OptionableOptionable Beta0.72 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:PHAT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.